Sumitomo Pharma Co. Ltd.

In News

Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa - PR Newswire

PR Newswire - Mar 23, 2026

Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia - Business Wire

Business Wire - Jun 10, 2026

New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH - BioSpace

BioSpace - May 18, 2026

New muscarinic M4 receptor antagonists reported in Sumitomo Pharma patent - BioWorld News

BioWorld News - Mar 02, 2026

Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease - BioInformant

BioInformant - Mar 11, 2026

Chugai Pharmaceutical Co Ltd (4519) - MSN

MSN - Jul 14, 2026

Sumitomo Pharma Q3 FY2025 slides: North American sales drive 408% profit surge - Investing.com

Investing.com - Feb 06, 2026

Sumitomo Pharma Shares Drop After Stem-Therapy Backing - Bloomberg.com

Bloomberg.com - Feb 19, 2026

Is Sumitomo Pharma (TSE:4506) Using Too Much Debt? - simplywall.st

simplywall.st - Jan 02, 2026

Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia - BioSpace

BioSpace - Jun 15, 2026

Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 - Business Wire

Business Wire - Jun 01, 2026

Expansion of the Pharmaceutical Business in Africa: Growing the Scope of Marubeni's Pharmaceutical Strategic Platform - marubeni.com

marubeni.com - Aug 19, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment